Helpdesk

Sales contact

Home > Resources > How a patient association gave rise to a company

How a patient association gave rise to a company

Last updated: June 24, 2024

A patient association in rare diseases is first and foremost families who all have one thing in common: they need a cure to be found and made available.

Discover how French company AtmosR worked with a patient association to tackle the need to find a cure for Ondine:

Subscribe to our newsletter

Kayentis accelerates US growth with 40% surge in bookings over...

Empowering patients through education – A structured approach to clinical...

Kayentis introduces its Patient Education Video Library to strengthen clinical...

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

SCOPE Europe 2025

OCT 14-15 2025 • Barcelona, Spain

SCOPE Europe | Summit for Clinical Operations Executives | October 14-15, 2025 |Barcelona, Spain

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

November 4 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

Oncology, PRO

The primary aim of Phase 1 oncology clinical trials is to determine the safety of a new treatment, and to...